|
Part C: OSE-279 600 mg - HLA-A2 negative Clinical Trials
1 actively recruiting trial
No change since May 2026
Pipeline
Phase 1/2: 1
Top Sponsors
- OSE Immunotherapeutics1
Indications
- Solid Advanced Tumor1
- NSCLC (Non-small Cell Lung Cancer)1
- Lymphoma1
- Lung Cancer1
- Cancer1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.